. 2019 Sep 13;8(10):1395–1404. doi: 10.1530/EC-19-0286
This work is licensed under a Table 1.
Risk of bias in included studies for the primary outcome – ‘change in weight’.
| Random error | Selection bias | Outcome | Total points | Notes | |||||
|---|---|---|---|---|---|---|---|---|---|
| Study | Prospective | Consecutive enrollment | Both genders | Hypothyroidism ruled out | Weight assessment by staff | Blinded to baseline weight | <5% missing data | ||
| Auriemma 2014 (5) | Yes | Yes | Yes | Yes | Yes | Unclear | No | 4 | Assessment from 3 to 6 months interval from baseline not included in report. 25/95 patients excluded due to treatment duration <12 months |
| Auriemma 2015 (26) | Yes | Yes | No | Yes | Yes | Unclear | No | 3 | Assessment from 3 to 6 months interval not included in report. 7/45 patients not included due to treatment duration <12 months |
| Barbosa 2014 (33) | Yes | Unclear | Yes | Yes | Yes | Unclear | No | 3 | 10/35 patients not included due to discontinuation of dopamine agonist therapy due to irregular supply. Exclusion criteria: chronic disease |
| Berinder 2011 (6) | Unclear | Unclear | Yes | No | Yes | Unclear | Yes | 2 | Exclusion criteria: diabetes and dyslipidemia |
| Ciresi 2013 (4) | No | Yes | Yes | Unclear | Yes | Unclear | No | 3 | Patients receiving hypoglycemic agents at baseline were excluded. One patient had diabetes, 13 patients with metabolic syndrome |
| Docknic 2002 (30) | Unclear | Unclear | Yes | Yes | Yes | Unclear | Yes | 4 | 52% of included patients were men |
| Inancli 2013 (29) | Yes | Unclear | No | Yes | Yes | Unclear | Yes | 3 | Exclusion criteria: CVD, diabetes and hypertension |
| Medic-Stojanovska 2015 (31) | Yes | Unclear | No | Yes | Yes | Unclear | Yes | 3 | Exclusion criteria: CVD, diabetes mellitus |
| Pala 2015 (27) | Yes | Yes | Yes | Unclear | Yes | Unclear | Yes | 5 | Only 1 male patient. Exclusion criteria: Diabetes, dyslipidemia |
| Silva 2011 (8) | Yes | Unclear | Yes | Yes | Yes | Unclear | Yes | 4 | 10/35 patients excluded due to discontinuation of DA therapy. 2 diabetes, Exclusion criteria: Acute or chronic diseases |
| Schwetz 2017 (25) | No | No | Yes | Unclear | Yes | Unclear | Yes | 3 | Patients failing to demonstrate normoprolactenemia at follow-up were excluded from analysis |
| Serri 2006 (7) | Yes | No | Yes | Unclear | Yes | Unclear | Yes | 4 | 7/15 patients were male. Exclusion criteria: CVD, HT, diabetes |
| Yavuz 2003 (28) | Yes | Unclear | No | Unclear | Yes | Unclear | Yes | 2 | No comorbidities |
| Iglesiasa 2016 (32) | No | Unclear | No | Unclear | N/A | N/A | No | 0 | |
aIglesias et al. did not report weight changes in response to dopamine receptor antagonist treatment.